Skip to main content
Quest Diagnostics

A Multiplex RT-qPCR Assay for Mutation Detection and Measurable Residual Disease Monitoring in Acute Myeloid Leukemia

AMP 2023

Association for Molecular Pathology

Salt Lake City, UT, Nov 14-18 2023

Poster presentation: A Multiplex RT-qPCR Assay for Mutation Detection and Measurable Residual Disease Monitoring in Acute Myeloid Leukemia

Authors: Yo J, Ma C, Racke F, Godsey J

Specialty: Oncology, Genetics

Related content

Publication
NGS defined measurable residual disease MRD after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
Conference Presentation
A novel highly sensitive approach for residual disease detection in AML using digital PCR
On-Demand Webinar
Hemepath Master Class Myeloid Neoplasms MPN MDS AML
Conference Presentation
Signatures of Disease and Resistance: FLT3 in Review
Test FAQ
AML Rapid Mutation Panel

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.